Additional studies are certainly needed to determine whether ADAM17 IHC will improve the prediction of clinical outcomes in bladder cancer therapy, although TCGA (The Cancer Genome Atlas) data provide the first evidence that ADAM17 mRNA expression alone is a significant prognostic indicator of survival in bladder cancer (Supplemental Figure S3) [41,42]. Here, ADAM17 is linked to urinary bladder carcinoma.